Nautilus Biotechnology Inc (NAUT) - Total Liabilities
Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has total liabilities worth $31.78 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Nautilus Biotechnology Inc cash conversion from operations to assess how effectively this company generates cash.
Nautilus Biotechnology Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Nautilus Biotechnology Inc to evaluate the company's liquid asset resilience ratio.
Nautilus Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Nautilus Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Acadian Timber Corp
TO:ADN
|
Canada | CA$273.87 Million |
|
LCNB Corporation
NASDAQ:LCNB
|
USA | $1.97 Billion |
|
Limoneira Co
NASDAQ:LMNR
|
USA | $120.30 Million |
|
Transgene SA
PA:TNG
|
France | €44.59 Million |
|
104 Corporation
TW:3130
|
Taiwan | NT$2.07 Billion |
|
Alro Slatina
RO:ALR
|
Romania | RON2.25 Billion |
|
Kisco Holdings
KO:001940
|
Korea | ₩134.23 Billion |
|
Companhia Brasileira de Distribuição
SA:PCAR3
|
Brazil | R$17.99 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Nautilus Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nautilus Biotechnology Inc (NAUT) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nautilus Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nautilus Biotechnology Inc (2018–2024)
The table below shows the annual total liabilities of Nautilus Biotechnology Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $34.01 Million | -15.42% |
| 2023-12-31 | $40.21 Million | +14.47% |
| 2022-12-31 | $35.13 Million | +0.73% |
| 2021-12-31 | $34.87 Million | -69.60% |
| 2020-12-31 | $114.73 Million | +23314.69% |
| 2019-12-31 | $490.00K | -99.65% |
| 2018-12-31 | $140.82 Million | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more